Results 31 to 40 of about 41,710 (302)

COVID-19 and chronological aging : senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? [PDF]

, 2020
COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family.
Auwerx, Blagosklonny, Blagosklonny, Blagosklonny, Colasurdo, Colson, Diaz-Quijano, Du, Erusalimsky, Gerontol, Gorospe, Hoffmann, Häkkinen, Jang, Li, Lisanti, Lisanti, Lu, Masternak, Munster, Musso, Nowakowski, Porter, Subbarao, Subbarao, Tanga, Tremblay, Wilce, Yaron, Yusof, Zhang   +30 more
core   +2 more sources

Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. [PDF]

, 2016
BACKGROUND: Apart from baseline glycated hemoglobin (HbA1c), little is known about clinical parameters that affect glycemic response to a dipeptidyl peptidase-4 (DPP4) inhibitor when used in routine clinical practice. We aimed to use a large primary care
Donnelly, Richard, Idris, Iskandar, Mamza, Jil, Mehta, Rajnikant   +3 more
core   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

Journal of Medical Case Reports, 2018
Background Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of ...
Yoshia Miyawaki, Ken-Ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada   +12 more
doaj   +1 more source

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo

Journal of Pharmacological Sciences, 2017
Saxagliptin, a potent and selective DPP-4 inhibitor, exhibits a slow dissociation from DPP-4. We investigated the sustained effects of saxagliptin on renal DPP-4 activity in a washout study using renal tubular (HK-2) cells, and in a pharmacodynamic study
Masako Uchii, Mariko Sakai, Yuhei Hotta, Satoshi Saeki, Naoya Kimoto, Akinori Hamaguchi, Tetsuya Kitayama, Shunji Kunori   +7 more
doaj   +1 more source

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

Journal of Diabetes Investigation, 2021
Aims/Introduction To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 ...
Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi   +15 more
doaj   +1 more source

Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats

Journal of Pharmacological Sciences, 2016
Saxagliptin, a potent and selective DPP-4 inhibitor, is characterized by its slow dissociation from DPP-4 and its long half-life and is expected to have a potent tissue membrane-bound DPP-4-inhibitory effect in various tissues.
Junichi Ikeda, Naoya Kimoto, Tetsuya Kitayama, Shunji Kunori   +3 more
doaj   +1 more source

Vildagliptin: the first innovative DDP-4 inhibitor

Сахарный диабет, 2010
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity
Edvin Villkhauer
doaj   +1 more source

Seprase: An overview of an important matrix serine protease [PDF]

, 2008
Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression.
Abbott, Abbott, Abbott, Acharya, Adams, Adams, Aertgeerts, Aimes, Alcolado, Aoyama, Ariga, Artym, Bangert, Barrett, Bauvois, Bermpohl, Birney, Bissell, Brendan F. O'Connor, Brown, Busek, Chen, Chen, Chen, Chen, Cheng, Cheng, Christiansen, Collins, Corpet, De Wever, Del Rosso, Dolznig, Dvorak, Edosada, Edosada, Fassnacht, Fidler, Fink, Flentke, Fulop, Garcia-Horsman, Garin-Chesa, Gerner, Ghersi, Ghersi, Ghersi, Gilmore, Goldstein, Goldstein, Goodman, Gorrell, Guex, Hofheinz, Huang, Huber, Huber, Ibrahim, Iwasa, Jin, Kelly, Kelly, Kelly, Kelly, Kloft, Koyama, Lee, Lee, Lee, Lee, Lee, Levy, Levy, Levy, Loeffler, Mathew, Mersmann, Milner, Monsky, Mori, Mueller, Nicholas, Niedermeyer, Niedermeyer, Niedermeyer, Oertel, Okada, Okada, Ollis, Pamela O'Brien, Park, Pineiro-Sanchez, Ramirez-Montagut, Rennex, Rettig, Rettig, Rettig, Rettig, Rosenblum, Samel, Scanlan, Schechter, Scott, Scott, Sieweke, Skubitz, Stremenova, Sun, Tahtis, Tran, Wang, Wang, Welt, Welt, Wesley, Zhang   +115 more
core   +1 more source

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Teneligliptin is a recently developed Dipeptidyl Peptidase 4 (DPP4) inhibitor. Teneligliptin is suitable for glycaemic control in Type 2 Diabetes Mellitus (T2DM) patients with renal impairment including end stage renal disease.
Kiran Shah
doaj   +1 more source